Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "biosimilars"

165 News Found

RDIF and Morepen announce production of test batch of Sputnik V
News | July 08, 2021

RDIF and Morepen announce production of test batch of Sputnik V

The first batch will be shipped to the Gamaleya Center for the quality control


Glenmark receives ANDA tentative approval for Nintedanib Capsules
News | June 26, 2021

Glenmark receives ANDA tentative approval for Nintedanib Capsules

According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination


Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
News | June 03, 2021

Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application

Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers


Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
News | May 31, 2021

Multiple catalysts ahead for Cadila Healthcare: HDFC Securities

Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.


New gen pharma leaders gear up to adopt digitalization, data analytics and customized R&D
Digitisation | May 27, 2021

New gen pharma leaders gear up to adopt digitalization, data analytics and customized R&D

The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.


Cadila Healthcare divests animal health business: ICICI Securities
News | May 16, 2021

Cadila Healthcare divests animal health business: ICICI Securities

The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.


Dr. Reddy's Sputnik V India price is Rs. 995.40
News | May 15, 2021

Dr. Reddy's Sputnik V India price is Rs. 995.40

The company is working closely with its six manufacturing partners in India


Biocon and Viatris receive EC approval for Biosimilar Bevacizumab
Biotech | April 28, 2021

Biocon and Viatris receive EC approval for Biosimilar Bevacizumab

The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer